Aerie Pharmaceuticals Inc. (AERI)

18.38
0.49 2.60
NASDAQ : Health Technology
Prev Close 18.87
Open 18.70
Day Low/High 18.30 / 18.93
52 Wk Low/High 17.51 / 50.10
Volume 229.77K
Avg Volume 1.33M
Exchange NASDAQ
Shares Outstanding 46.32M
Market Cap 880.56M
EPS -5.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
First Week Of January 2020 Options Trading For Aerie Pharmaceuticals (AERI)

First Week Of January 2020 Options Trading For Aerie Pharmaceuticals (AERI)

Investors in Aerie Pharmaceuticals Inc saw new options become available this week, for the January 2020 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AERI options chain for the new January 2020 contracts and identified one put and one call contract of particular interest.

Aerie Pharmaceuticals Announces Agreement To Acquire Avizorex Pharma, S.L. To Advance Its Dry Eye Program

Aerie Pharmaceuticals Announces Agreement To Acquire Avizorex Pharma, S.L. To Advance Its Dry Eye Program

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) ("Aerie"), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and...

Aerie Pharmaceuticals To Present At The Stifel 2019 Healthcare Conference

Aerie Pharmaceuticals To Present At The Stifel 2019 Healthcare Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Reports Third Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance And Provides Business Update

Aerie Pharmaceuticals Reports Third Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance And Provides Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Announces Positive Topline Results For Netarsudil Ophthalmic Solution In Phase 2 Study Conducted In Japan

Aerie Pharmaceuticals Announces Positive Topline Results For Netarsudil Ophthalmic Solution In Phase 2 Study Conducted In Japan

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals To Announce Third Quarter 2019 Financial Results And Host Conference Call On Wednesday, November 6, 2019

Aerie Pharmaceuticals To Announce Third Quarter 2019 Financial Results And Host Conference Call On Wednesday, November 6, 2019

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Announces The Appointment Of David A. Hollander, M.D., M.B.A., As Chief Research & Development Officer

Aerie Pharmaceuticals Announces The Appointment Of David A. Hollander, M.D., M.B.A., As Chief Research & Development Officer

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Completes Enrollment In The Phase 2 Trial Of AR-1105 (Dexamethasone Intravitreal Implant) In Patients With Macular Edema Associated With Retinal Vein Occlusion Ahead Of Schedule

Aerie Pharmaceuticals Completes Enrollment In The Phase 2 Trial Of AR-1105 (Dexamethasone Intravitreal Implant) In Patients With Macular Edema Associated With Retinal Vein Occlusion Ahead Of Schedule

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and...

Aerie Pharmaceuticals Announces Appointment Of Charlene E. Davis, Esq., As Vice President And Chief Compliance Officer

Aerie Pharmaceuticals Announces Appointment Of Charlene E. Davis, Esq., As Vice President And Chief Compliance Officer

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

First Week Of AERI May 2020 Options Trading

First Week Of AERI May 2020 Options Trading

Investors in Aerie Pharmaceuticals Inc saw new options begin trading this week, for the May 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Aerie Pharmaceuticals To Present At The 2019 Cantor Fitzgerald Global Healthcare Conference

Aerie Pharmaceuticals To Present At The 2019 Cantor Fitzgerald Global Healthcare Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Receives Positive CHMP Opinion For Rhokiinsa® In The European Union

Aerie Pharmaceuticals Receives Positive CHMP Opinion For Rhokiinsa® In The European Union

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

These 2 Biotech Stocks Are Seeing Insider Buying Activity

These 2 Biotech Stocks Are Seeing Insider Buying Activity

We're focused on Progenics Pharmaceuticals and Aerie Pharmaceuticals.

RSI Alert: Aerie Pharmaceuticals (AERI) Now Oversold

RSI Alert: Aerie Pharmaceuticals (AERI) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aerie Pharmaceuticals To Offer $250 Million Convertible Senior Notes Due 2024

Aerie Pharmaceuticals To Offer $250 Million Convertible Senior Notes Due 2024

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals To Present At The H.C. Wainwright Global Investment Conference

Aerie Pharmaceuticals To Present At The H.C. Wainwright Global Investment Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Announces Appointment Of Luis Vargas, M.D., As Medical Director, Medical Affairs

Aerie Pharmaceuticals Announces Appointment Of Luis Vargas, M.D., As Medical Director, Medical Affairs

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial Of AR-13503 Sustained Release Intravitreal Implant In Patients With Neovascular Age-Related Macular Degeneration And Diabetic Macular Edema

Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial Of AR-13503 Sustained Release Intravitreal Implant In Patients With Neovascular Age-Related Macular Degeneration And Diabetic Macular Edema

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CCS, K, OCSL, SSRM Downgrades: AIMC, CCOI, DBI, HAFC, HMST, ICUI, SRAX Initiations: AERI, APTX, PS, ROSEU Read on to get TheStreet Quant Ratings' detailed report:

Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance And Provides Business Update

Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance And Provides Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals To Announce Second Quarter 2019 Financial Results And Host Conference Call On Wednesday, August 7, 2019

Aerie Pharmaceuticals To Announce Second Quarter 2019 Financial Results And Host Conference Call On Wednesday, August 7, 2019

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

First Week Of AERI September 20th Options Trading

First Week Of AERI September 20th Options Trading

Investors in Aerie Pharmaceuticals Inc saw new options become available this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AERI options chain for the new September 20th contracts and identified one put and one call contract of particular interest.

Aerie Pharmaceuticals Completes Enrollment Of The Netarsudil Ophthalmic Solution Phase 2 Clinical Trial In Japan Months Ahead Of Schedule

Aerie Pharmaceuticals Completes Enrollment Of The Netarsudil Ophthalmic Solution Phase 2 Clinical Trial In Japan Months Ahead Of Schedule

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and...

Aerie Pharmaceuticals Announces Appointment Of Jeffrey Calabrese, CPA, As Director Of Accounting

Aerie Pharmaceuticals Announces Appointment Of Jeffrey Calabrese, CPA, As Director Of Accounting

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals To Present At Two Upcoming Investor Conferences

Aerie Pharmaceuticals To Present At Two Upcoming Investor Conferences

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals To Present At The Jefferies 2019 Healthcare Conference

Aerie Pharmaceuticals To Present At The Jefferies 2019 Healthcare Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results And Provides Business Update

Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results And Provides Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility With Deerfield Management, Increasing Availability To $200M

Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility With Deerfield Management, Increasing Availability To $200M

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and...

Aerie Pharmaceuticals To Announce First Quarter 2019 Financial Results And Host Conference Call On Tuesday, May 7, 2019

Aerie Pharmaceuticals To Announce First Quarter 2019 Financial Results And Host Conference Call On Tuesday, May 7, 2019

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Announces Acceptance Of Its Investigational New Drug Application For AR-13503 Sustained Release Implant

Aerie Pharmaceuticals Announces Acceptance Of Its Investigational New Drug Application For AR-13503 Sustained Release Implant

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

TheStreet Quant Rating: D- (Sell)